About 258 results

ALLMedicine™ Alopecia Universalis Center

Research & Reviews  82 results

Estimation of CD3, CD4, and CD8 in Iraqi patients with alopecia areata and alopecia uni...
Journal of Cosmetic Dermatology; Aldaffaie STH, Hussein TA et. al.

Nov 4th, 2021 - Alopecia areata is considered to be an autoimmune disease characterized by T-cell response and production of cytokines around the anagen stage. The aim of this study was to assess T cells in blood using immune biomarkers (CD3, CD4, and CD8) in pat...

Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.
https://doi.org/10.1007/s12016-021-08883-0 10.1016/j.jaad.2020.06.047 10.1016/j.jaad.2019.08.032 10.1016/j.jaad.2017.04.1141 10.1007/s40265-020-01293-0 10.1111/exd.14073 10.1016/j.jaut.2018.12.001 10.1111/bjd.16808 10.1016/j.jaci.2019.08.035 10.1111/jdv.15489 10.1016/j.jaci.2017.10.028 10.1016/j.jaad.2017.04.1142 10.1016/j.jaad.2005.12.007 10.1016/s0190-9622(98)70499-2 10.1016/j.jaad.2009.02.006 10.1086/511442 10.1038/nature09114 10.1038/JID.2015.402 10.1038/jid.2012.129 10.1016/j.ebiom.2020.102810 10.1016/j.jisp.2020.04.003 10.1111/exd.13123 10.1111/exd.13986 10.1111/exd.14155 10.1056/NEJMra1103442 10.1016/j.autrev.2016.03.008 10.1111/j.1365-2133.2006.07377.x 10.1111/j.0022-202X.2004.23580.x 10.1038/nm.3645 10.1038/nm.3685 10.1016/j.jaut.2018.04.001 10.1111/jdv.14775 10.1001/jamadermatol.2014.504 10.1159/000350933 10.1111/1346-8138.12978 10.1111/jdv.12932 10.1016/j.alit.2019.07.009 10.1371/journal.pone.0094260 10.1007/s00403-015-1539-1 10.1111/exd.14129 10.1001/jamadermatol.2014.62 10.1016/j.jid.2016.04.004 10.1046/j.0022-202x.2001.01583.x 10.1111/ced.12556 10.5152/balkanmedj.2016.16190 10.1111/ijd.14753 10.1001/jamadermatol.2014.3324 10.1016/j.jaad.2009.04.031 10.4103/0378-6323.102361 10.1111/ced.12471 10.1111/exd.14027 10.1016/j.jaad.2020.06.1026 10.1016/j.jdermsci.2010.03.009 10.1038/nature18848 10.1034/j.1600-0625.2003.120104.x 10.1111/jdv.15885 10.1111/bjd.19461 10.1371/journal.pone.0215206 10.1038/gene.2017.4 10.1016/j.molmed.2011.07.005 10.3389/fimmu.2019.00856 10.1111/j.1365-2133.2011.10646.x 10.1016/j.jid.2017.09.046 10.1002/jcb.28700 10.1016/j.jaad.2018.12.047 10.1007/s12016-017-8620-9 10.1016/j.jaad.2009.05.001 10.5826/dpc.0904a05 10.1159/000249182 10.1016/j.jaad.2008.07.062 10.1016/j.clindermatol.2013.06.003 10.1111/ijd.13866 10.1111/1346-8138.14283 10.1016/j.jaad.2012.02.013 10.4103/0019-5154.84768 10.1159/000490459 10.1016/j.jaad.2011.02.017 10.1016/j.det.2012.08.001 10.1111/1346-8138.12591 10.1111/j.1365-2133.2012.10955.x 10.1111/jdv.15582 10.1016/j.jaad.2006.05.008 10.1111/ajd.12941 10.1159/000442816 10.1016/j.jaad.2018.08.059 10.1111/bjd.18883 10.1111/bjd.19024 10.1007/s40257-020-00545-9 10.1016/j.jaad.2015.04.049 10.1016/j.jaad.2019.11.066 10.1097/00055735-200012000-00016 10.1016/j.jaad.2004.10.873 10.1016/j.jaad.2015.12.026 10.2147/dddt.S214907 10.1111/jdv.15545 10.1111/ijd.14933 10.1001/jamadermatol.2018.2312 10.1007/s13555-018-0226-5 10.1111/exd.13758 10.1016/j.jaad.2019.10.043 10.1016/j.jaad.2019.04.053 10.1016/j.jaad.2015.12.055 10.1111/1346-8138.13933 10.1038/nrrheum.2015.167 10.1016/j.immuni.2012.03.014 10.1016/j.jaad.2016.12.005 10.1038/ncomms6966 10.1172/jci.insight.89776 10.1016/j.jid.2018.01.032 10.1016/j.jaad.2016.09.007 10.1016/j.jaad.2016.09.006 10.1016/j.jaad.2018.08.041 10.1016/j.jaad.2018.12.041 10.1172/jci.insight.89790 10.1016/j.ebiom.2015.02.015 10.1016/j.jdcr.2019.07.005 10.1080/17512433.2020.1702878 10.1007/s40744-020-00258-9 10.1126/sciadv.1500973 10.1111/jdv.15489 10.3389/fimmu.2019.02847 10.1177/120347541201600407 10.1016/j.jaad.2005.03.039 10.1001/archdermatol.2009.264 10.1016/j.jaad.2007.10.645 10.1016/j.jaci.2015.06.032 10.1007/s00403-018-1853-5 10.1016/j.jaad.2020.08.051 10.1111/bjd.18976 10.1016/j.jdcr.2020.10.010 10.1111/bjd.16711 10.1111/jdv.16493 10.1016/j.jdcr.2017.11.020 10.3315/jdcr.2010.1041 10.1684/ejd.2013.2221 10.1016/j.jaci.2015.11.001 10.1111/pde.13699 10.1684/ejd.2020.3866 10.1016/j.jdcr.2019.10.012 10.1159/000499030 10.1007/s40265-014-0218-4 10.1016/j.jdermsci.2014.11.009 10.1080/09546634.2019.1616046 10.1684/ejd.2019.3576 10.1007/s00403-018-1876-y 10.1016/j.jaad.2017.11.056 10.1684/ejd.2020.3749 10.1080/09546634.2019.1589641 10.1016/j.jaad.2017.05.034 10.1038/nrd1989 10.1016/j.jaad.2020.09.091 10.1136/annrheumdis-2016-210724 10.1016/j.jisp.2020.05.002 10.1111/j.1524-4725.2012.02394.x 10.1111/bjd.12397 10.1111/jocd.12858 10.1016/j.jdcr.2015.07.004 10.1111/dth.12989 10.1056/NEJMoa1105143 10.1038/nrd.2018.148 10.1016/j.jid.2020.08.015 10.1016/j.jisp.2017.10.013 10.1016/j.jaad.2020.03.102 10.1016/j.jaad.2014.11.006 10.1159/000468991 10.5021/ad.2017.29.6.755 10.1016/j.jaad.2015.09.071 10.1016/j.jaad.2019.04.047 10.1111/j.1346-8138.2007.00401.x 10.1111/j.1346-8138.2009.00647.x 10.1046/j.1365-2222.2003.01701.x 10.1016/s0002-9394(14)70870-0 10.1111/j.1365-2133.2010.09685.x 10.1111/j.1468-3083.2009.03543.x 10.1016/j.jaad.2009.01.027 10.1016/j.jaad.2008.08.029 10.1159/000371416 10.1080/09546634.2017.1330527 10.1111/pde.12920 10.1016/j.jaad.2017.06.027 10.1159/000494613 10.1016/j.jaad.2017.03.024 10.1016/j.jdcr.2019.07.005 10.1002/acr.24007 10.1002/art.41316
Clinical Reviews in Allergy & Immunology; Zhou C, Li X et. al.

Aug 18th, 2021 - Alopecia areata (AA) is a common chronic tissue-specific autoimmune disease, resulting in hair loss, that affects up to 2% of the general population. The exact pathobiology of AA has still remained elusive, while the common theory is the collapse ...

Alopecia Universalis Occurring after Alemtuzumab Treatment for Multiple Sclerosis. A Tw...
International Journal of Environmental Research and Publi... Borriello G, Ianniello A et. al.

Jul 25th, 2021 - Alopecia Universalis (AU) is the most severe form of Alopecia Areata and is caused by cytotoxic T-cells reacting with follicular autoantigens, producing complete loss of scalp and body hair. Alemtuzumab is a highly efficacious monoclonal antibody ...

T-Cell-Driven Fibroinflammation Inducing Follicular Dedifferentiation in Alopecia Areat...
The American Journal of Dermatopathology; Kossard S, Sheriff T et. al.

Jun 17th, 2021 - The definition of IgG4-related diseases incorporates a broad range of systemic diseases particularly a subset dominated by fibroinflammation. CD4+cytotoxic T cells have emerged as the major driving force for the fibroinflammation, and the pathogen...

Prediction of the Risk of Alopecia Areata Progressing to Alopecia Totalis and Alopecia ...
Dermatology (Basel, Switzerland); Zhang T, Nie Y

May 19th, 2021 - Alopecia areata (AA) is an autoimmune disease typified by nonscarring hair loss with a variable clinical course. Although there is an increased understanding of AA pathogenesis and progress in its treatments, the outcome of AA patients remains unf...

see more →

Clinicaltrials.gov  3 results

A Study of Secukinumab for the Treatment of Alopecia Areata

Mar 11th, 2021 - Alopecia areata is a medical condition, in which the hair falls out in patches. The hair can fall out on the scalp or elsewhere on the face and body. Alopecia areata is an autoimmune skin disease, which means that the immune system is recognizing ...

Intralesional Steroids in the Treatment of Alopecia Areata

Jun 6th, 2019 - Alopecia areata (AA) is a major medical problem and is the most prevalent autoimmune disease in the US. AA represents the second most common form of hair loss and causes significant disfigurement and psychological distress to affected individuals....

Alopecia Areata Registry

May 14th, 2019 - Alopecia areata is a condition in which hair is lost either from part of the scalp, all of the scalp, or the entire body, and it affects 1% to 2% of the population. It is thought to be an autoimmune disease and in some cases the disease is heredit...

see more →

News  18 results

JAK Inhibitor Provides Impressive Hair Growth for Patients With Alopecia Areata

Oct 4th, 2021 - Baricitinib, an oral inhibitor of Janus kinase (JAK) types 1 and 2, produced substantial rates of hair growth with acceptable tolerability for patients with alopecia areata, according to the results of two phase 3 trials presented at the European ...

Review looks at natural course of alopecia areata in young children
Jake Remaly

Sep 26th, 2019 - Most children who develop alopecia areata before age 4 years have mild disease with less than 50% hair loss, and present between ages 2 and 4, according to a retrospective chart review of 125 children. Almost 90% of the children presented between.

Another JAK Inhibitor Shows Promise for Alopecia Areata

Mar 11th, 2019 - The Janus kinase (JAK) inhibitor CTP-543 (Concert Pharmaceuticals) is effective for the treatment of moderate to severe alopecia areata, according to interim results from a phase 2a randomized safety and efficacy study (NCT03137381). "We've identi...

JAK Inhibitors Promising for Alopecia Areata

Sep 17th, 2018 - PARIS — Two investigational oral Janus kinase (JAK) inhibitors are safe and effective for patients with moderate to severe hair loss, according to 24-week interim findings from a randomized, double-blind, placebo-controlled, multicenter phase 2 tr...

JAK Inhibitors Promising for Alopecia Areata

Sep 17th, 2018 - PARIS — Two investigational oral Janus kinase (JAK) inhibitors are safe and effective for patients with moderate to severe hair loss, according to 24-week interim findings from a randomized, double-blind, placebo-controlled, multicenter phase 2 tr...

see more →